Tracon Pharmaceuticals, Inc.
TCONDelisted Jul 19, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001394319
Tracon Pharmaceuticals, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Mar 13, 2024; 29 institutions reported holding it in 13F filings for Q1 2024, worth $1.39M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q1 2024, +5 vs. previous quarter
- 13F value
- $1.39M
- Reported value at the end of Q1 2024
- Superinvestors holding
- 0
- At the end of Q1 2024
Superinvestors holding TCON, Q1 2024
No superinvestor reported holding TCON at the end of Q1 2024.
Latest insider trades
Open-market purchases and sales by Tracon Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2023 (view filing)4:05 PM ET | Nov 10 | 4 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −4.76M | $0.2942 | −$1.40M | −100.0%0 after | 2 lots |
| Apr 28, 2023 (view filing) | Apr 26-27 | 2 days | Theuer CharlesPresident and CEO | PPurchase | +51.0K | $0.7429 | +$37.9K | +14.6%399.4K after | 2 lots |
| Mar 13, 2023 (view filing) | Mar 9 | 4 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +174.5K | $1.38 | +$240.8K | +4.2%4.32M after | |
| Mar 2, 2023 (view filing) | Feb 28-Mar 1 | 2 days | Theuer CharlesPresident and CEO | PPurchase | +5.00K | $1.52 | +$7.60K | +1.5%344.9K after | 2 lots |
| Jan 19, 2023 (view filing) | Jan 18 | 1 day | Theuer CharlesPresident and CEO | PPurchase | +6.80K | $1.62 | +$11.0K | +2.0%339.9K after | |
| Jan 19, 2023 (view filing) | Dec 21, 2022 | 29 daysLate | Larue William RDirector | SSale | −120 | $1.26 | −$151.2 | −1.5%7.76K after | |
| Jan 3, 2023 (view filing) | Dec 29, 2022 | 5 days | Brown Scott B.Chief Financial Officer | PPurchase | +3.50K | $1.49 | +$5.21K | +19.3%21.6K after | |
| Dec 16, 2022 (view filing) | Dec 14 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +167.5K | $1.26 | +$210.5K | +61.5%440.0K after | 2 lots |
| Dec 15, 2022 (view filing) | Dec 14 | 1 day | Theuer CharlesPresident and CEO | PPurchase | +23.0K | $1.29 | +$29.7K | +7.4%333.1K after | |
| Dec 8, 2022 (view filing)6:49 PM ET | Dec 6 | 2 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.01 per share | −1.54K | $1.44 | −$2.22K | 0.0%4.01M after |
Top 10 13F holders, Q1 2024
The largest institutional positions in Tracon Pharmaceuticals, Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| LPL Financial LLC | 450,650 | $193.7K | 0.00% | +450,650 | New |
| Acadian Asset Management LLC | 413,909 | $176.0K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 388,985 | $167.2K | 0.00% | −23,286−5.6% | Reduced |
| Renaissance Technologies LLC | 300,238 | $129.0K | 0.00% | +202,200+206.2% | Added |
| Geode Capital Management, LLC | 286,709 | $123.2K | 0.00% | +77,923+37.3% | Added |
| Vanguard Group Inc | 262,772 | $112.9K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 260,084 | $111.8K | 0.00% | −1,178−0.5% | Reduced |
| Jane Street Group, LLC | 182,307 | $78.4K | 0.00% | +182,307 | New |
| UBS Group AG | 91,333 | $39.3K | 0.00% | +91,333 | New |
| Johnson & Johnson | 84,003 | $36.1K | 0.00% | 00.0% | Unchanged |